Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 5/20 | 0.36 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473373 | 0.88 | TK1 (0.38) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473410 | 0.88 | TK1 (0.38) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473405 | 0.85 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473356 | 0.85 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473381 | 0.81 | LMNA (0.44) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473421 | 0.81 | LMNA (0.44) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16473393 | 0.74 | TK1 (0.43) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13615532 | 0.73 | ALDH1A1 (0.45) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14565243 | 0.71 | TK2 (0.55) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL18513323 | 0.70 | TK2 (0.49) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029335-B2 | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140106451-A1 | SUBSTITUTED 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140106451-A1 | SUBSTITUTED 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | TK1 426/4885ALDH1A1 3079/4885LMNA 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.